Showing results (121-130 of 189) with videos related to

Sort By:
Pageof 19
Cells|September 28, 2021
Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal MelanomasJoanna P Wróblewska, Dora Dias-Santagata, Adam Ustaszewski, et al.
International Journal of Dermatology|July 10, 2020
Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndromeBerenika Olszewska, Anton Żawrocki, Joanna Lakomy, et al.
Cancers|November 17, 2018
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 PatientsMagdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, et al.
Pathology Oncology Research : POR|March 20, 2012
Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancerAnna Zaczek, Aleksandra Markiewicz, Anna Supernat, et al.
Postepy Dermatologii I Alergologii|April 4, 2022
Interleukin-31 is overexpressed in skin and serum in cutaneous T-cell lymphomas but does not correlate to pruritusBerenika Olszewska, Anton Żawrocki, Jolanta Gleń, et al.
Clinical & Experimental Metastasis|August 4, 2016
Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancerMaciej Bobowicz, Marcin Skrzypski, Piotr Czapiewski, et al.
International Journal of Molecular Sciences|June 4, 2020
Expression of HTRA Genes and Its Association with Microsatellite Instability and Survival of Patients with Colorectal CancerDorota Zurawa-Janicka, Jarek Kobiela, Tomasz Slebioda, et al.
Pathology|January 25, 2022
High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case seriesMichał Kunc, Rafał Pęksa, Gabor Cserni, et al.
Oncotarget|November 17, 2016
Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cellsDominika Piasecka, Kamila Kitowska, Dominika Czaplinska, et al.
Oncotarget|December 8, 2016
An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy numberEwa Szutowicz-Zielińska, Krzysztof Konopa, Anna Kowalczyk, et al.
Pageof 19